The FDA approved Takeda’s Orzeyful (oveporexton), described as the first therapy designed to address the underlying cause of narcolepsy type 1 in adults. The approval follows clearance from China’s NMPA in July and positions orexin receptor 2 agonism as a disease-mechanism approach rather than purely symptomatic control. In diagnostics, the FDA also cleared Labcorp’s PGDx elio tissue complete as a companion diagnostic for BRAF V600E and V600K mutations in melanoma. The ready-to-use, hybrid-capture NGS workflow is designed to identify patients for FDA-approved targeted therapies and aims to reduce turnaround friction for hospitals. On the radiopharma side, FDA issued a complete response letter for ITM Isotope’s ITM-11 (177Lu-edotreotide) due to manufacturing issues at a third-party facility, delaying progress for gastroenteropancreatic neuroendocrine tumors. Overall, the approvals and setbacks show the dual track facing developers: mechanistic therapeutics gaining regulatory traction while manufacturing readiness and companion-diagnostic workflow integration become decisive for speed to treatment.